A 2 Year Extension to a 36-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-Acute Myocardial Infarction Patients When Added to Optimized Standard Therapy.

Trial Profile

A 2 Year Extension to a 36-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-Acute Myocardial Infarction Patients When Added to Optimized Standard Therapy.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Aliskiren (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis
  • Most Recent Events

    • 28 Apr 2012 Planned number of patients changed from 500 to 800 as reported by European Clinical Trials Database record.
    • 23 Jun 2010 New source identified and integrated (Clinical Trials Registry - India record).
    • 23 Jun 2010 Status changed from active, no longer recruiting to recruiting as reported by Clinical Trials Registry - India record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top